

PRELIMINARY PROGRAM

EMN

1st European Myeloma Network Meeting

Turin
April 19-21, 2018

Lingotto Conference Center

www.emn2018.com



UNDER THE AUSPICES OF:

CITTÀ DI TORINO

REGIONE PIEMONTE

UNIVERSITÀ DI TORINO

AZIENDA OSPEDALIERO-UNIVERSITARIA

Città della Salute e della Scienza di Torino – Presidio Ospedaliero Le Molinette

SIE – Società Italiana di Ematologia

SIES – Società Italiana di Ematologia Sperimentale

**GITMO – Gruppo Italiano per il Trapianto di Midollo Osseo,
cellule staminali emopoietiche e terapia cellulare**

AIL – Associazione Italiana contro le Leucemie-linfomi e mieloma Onlus

GIMEMA – Gruppo Italiano Malattie EMatologiche dell'Adulto

**IPASVI – Federazione Nazionale Collegi Infermieri Professionali,
Assistenti sanitari, Vigilatrici d'infanzia**

WELCOME MESSAGE

Dear Colleagues and Friends,

It is my great pleasure and honor to invite you to attend the 1st EMN 2018 meeting taking place this year, from April 19 - 21, 2018, in Turin, Italy.

This event is organized under the umbrella of the European Myeloma Network and it seeks to go beyond national boundaries by including research groups from all over Europe.

The location of the meeting is Lingotto Conference Center, an ideal venue to host important international congresses and big events. At the foot of the Alps, Turin is a majestic city, the former capital of Italy, easily reachable and well connected to the rest of Europe. Here you will enjoy both the meeting and this fascinating city.

I am sure the EMN2018 will be a great opportunity for everyone to strengthen bonds between teams and start new collaborations, which will ultimately result in new opportunities and advances for the benefit of patients.

I am very much looking forward to welcoming you soon.



Mario Boccardo – Turin
On behalf of the EMN2018 Board

SCIENTIFIC BOARD

Mario Boccardo (Italy)
Hermann Einsele (Germany)
Maria-Victoria Mateos (Spain)
Philippe Moreau (France)
Pieter Sonneveld (The Netherlands)

SCIENTIFIC SECRETARIAT

Francesca Gay (Italy)
Niels van de Donk (The Netherlands)

FACULTY

Michel	Attal	Toulouse, France
Hervé	Avet-Loiseau	Toulouse, France
Annalisa	Bernardini	Turin, Italy
Juan	Bladé	Barcelona, Spain
Mario	Boccardo	Turin, Italy
Felice N.	Bombaci	Turin, Italy
Patricia W.C.	Bosman	Amsterdam, The Netherlands
Sara	Bringhen	Turin, Italy
Michele	Cavo	Bologna, Italy
Gordon	Cook	Leeds, United Kingdom
Michel	Delforge	Leuven, Belgium
Meletios A.	Dimopoulos	Athens, Greece
Christoph	Driessen	St. Gallen, Switzerland
Brian G.M.	Durie	Los Angeles, USA
Hermann	Einsele	Würzburg, Germany
Monika	Engelhardt	Freiburg, Germany
Francesca	Gay	Turin, Italy
Nicola	Giuliani	Parma, Italy
Hartmut	Goldschmidt	Heidelberg, Germany
Roman	Hájek	Ostrava, Czech Republic
Jean-Luc	Harousseau	Nantes, France
Jens	Hillengas	Buffalo, USA
Davine	Hofste op Bruinink	Boston, USA
Graham	Jacskon	Newcastle upon Tyne, United Kingdom
Hans E.	Johnsen	Aalborg, Denmark
Martin F.	Kaiser	London, United Kingdom
Efstathios	Kastritis	Athens, Greece
Marie José	Kersten	Amsterdam, The Netherlands
Sigurdur	Kristinsson	Reykjavík, Iceland
Robert A.	Kyle	Rochester, USA
Alessandra	Larocca	Turin, Italy
Xavier	Leleu	Poitiers, France
Sarah J.	Lonergan	Rotterdam, The Netherlands
Sagar	Lonial	Atlanta, USA

Heinz	Ludwig	Vienna, Austria
Fabio	Malavasi	Turin, Italy
Maria-Victoria	Mateos	Salamanca, Spain
Philip L.	McCarthy	Buffalo, USA
Giampaolo	Merlini	Pavia, Italy
Monique	Minnema	Utrecht, The Netherlands
Mohamad	Mohty	Paris, France
Vittorio	Montefusco	Milan, Italy
Philippe	Moreau	Nantes, France
Gareth J.	Morgan	Little Rock, USA
Nikhil C.	Munshi	Boston, USA
Pellegrino	Musto	Rionero in Vulture, Italy
Inger S.	Nijhof	Amsterdam, The Netherlands
Enrique M.	Ocio	Salamanca, Spain
Massimo	Offidani	Ancona, Italy
Albert	Oriol	Barcelona, Spain
Roger	Owen	Leeds, United Kingdom
Giovanni	Palladini	Pavia, Italy
Maria Teresa	Petrucci	Rome, Italy
Ananda	Plate	Brussels, Belgium
Torben	Plesner	Vejle, Denmark
Marc S.	Raab	Heidelberg, Germany
Paula	Rodriguez Otero	Navarra, Spain
Laura	Rosiñol	Barcelona, Spain
Pieter	Sonneveld	Rotterdam, The Netherlands
Christian	Straka	Berg, Germany
Evangelos	Terpos	Athens, Greece
Steven P.	Treon	Boston, USA
Rossella	Troia	Turin, Italy
Niels	van de Donk	Amsterdam, The Netherlands
Anders	Waage	Trondheim, Norway
Elena	Zamagni	Bologna, Italy
Renato	Zambello	Padova, Italy
Sonja	Zweegman	Amsterdam, The Netherlands

TIMETABLE

Thursday, April 19, 2018	Friday, April 20, 2018	Saturday, April 21, 2018
	8.00 - 9.00 MEET THE EXPERTS	8.00 - 9.00 MEET THE EXPERTS
11.30 - 11.40 OPENING CEREMONY	9.00 - 10.15 TREATMENT STRATEGY IN MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS	9.00 - 10.15 TREATMENT STRATEGY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: NOVEL THERAPIES, WHEN AND IN WHICH PATIENTS?
11.40 - 11.55 OPENING LECTURE	10.15 - 11.10 RECOMMENDATIONS AND CHALLENGES: HOW TO MAKE SENSE OF THE MANY TREATMENT OPTIONS AVAILABLE AT DIAGNOSIS	10.15 - 10.55 BEST ABSTRACTS II - ORAL PRESENTATIONS
11.55 - 12.45 MGUS AND SMM: RECOMMENDATIONS AND CHALLENGES	11.10 - 11.30 COFFEE BREAK and POSTER VIEWING	10.55 - 11.30 COFFEE BREAK and POSTER VIEWING
12.45 - 13.45 LUNCH and POSTER VIEWING	11.30 - 13.00 JANSSEN SPONSORED SYMPOSIUM Multiple Myeloma: what are your goals for treating patients in 2018?	11.30 - 12.50 RECOMMENDATIONS AND CHALLENGES: HOW TO MAKE SENSE OF THE MANY TREATMENT OPTIONS AVAILABLE AT RELAPSE
13.45 - 15.15 CELGENE SPONSORED SYMPOSIUM IMiD-based treatments for Multiple Myeloma	13.00 - 13.30 PATIENT PERSPECTIVE: PATIENT ASSOCIATION TALKS	12.50 - 13.30 SIDE EFFECTS MANAGEMENT
15.15 - 16.00 MULTIPLE MYELOMA BIOLOGY AND GENOMICS	13.30 - 14.30 LUNCH and POSTER VIEWING	13.30 - 13.40 CONCLUSIONS AND FINAL GREETINGS
16.00 - 16.30 COFFEE BREAK and POSTER VIEWING	14.30 - 16.00 PRIME ONCOLOGY SPONSORED SYMPOSIUM SUPPORTED BY BRISTOL-MYERS SQUIBB Fitting the pieces together: treatment decisions for patients with relapsed/refractory Multiple Myeloma	
16.30 - 18.00 AMGEN SPONSORED SYMPOSIUM Multiple Myeloma - Treatment strategies in a radically changing therapy landscape	16.00 - 16.50 SPECIAL CONDITIONS - WALDENSTRÖM MACROGLOBULINEMIA	
18.00 - 19.00 MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA	16.50 - 17.20 COFFEE BREAK and POSTER VIEWING	
19.00 - 19.40 AGGRESSIVE DISEASE - EXTRAMEDULLARY DISEASE/PLASMA CELL LEUKEMIA	17.20 - 18.10 SPECIAL CONDITIONS - AMYLOID LIGHT-CHAIN AMYLOIDOSIS	
19.40 - 20.30 WELCOME COCKTAIL	18.10 - 18.50 BEST ABSTRACTS I - ORAL PRESENTATIONS	

THURSDAY, APRIL 19, 2018

11.30-11.40 **OPENING CEREMONY**

11.40-11.55 **OPENING LECTURE**

Myeloma from past to present - R.A. Kyle

11.55-12.45 **MGUS AND SMM: RECOMMENDATIONS AND CHALLENGES**

Chairmen: R.A. Kyle, M.V. Mateos

MGUS and SMM - S. Kristinsson

M protein related disease - J. Bladé

What kind of trials do we need in the future to address open issues in SMM? - M.V. Mateos

Panel discussion

12.45-13.45 **LUNCH and POSTER VIEWING**

13.45-15.15 **CELGENE SPONSORED SYMPOSIUM
IMiD-based treatments for Multiple Myeloma**

Chairman: M.V. Mateos

Optimizing IMiD treatment in MM - M.V. Mateos

Practical implications of IMiD therapy - F. Gay

New targets and synergy of IMiD combinations - N. van de Donk

15.15-16.00 **MULTIPLE MYELOMA BIOLOGY AND GENOMICS**

Chairmen: N.C. Munshi, P. Sonneveld

Biology of Multiple Myeloma - M.S. Raab

DEBATE: CAN GENETIC ABNORMALITIES BE TARGETED?

- Applicable approach? YES - M.F. Kaiser
- Applicable approach? NO - P. Sonneveld

Panel discussion

16.00-16.30 **COFFEE BREAK and POSTER VIEWING**

16.30-18.00 **AMGEN SPONSORED SYMPOSIUM
Multiple Myeloma – Treatment strategies in a radically changing
therapy landscape**

Chairman: M. Cavo

Shaping a future for frontline treatment - A. Larocca

Myeloma relapse: deepening responses and extending survival - A. Oriol

18.00-19.00 **MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA**

Chairmen: B.G.M. Durie, J. Hillengass

MRD techniques - H. Avet-Loiseau

Imaging techniques - E. Zamagni

RECOMMENDATIONS AND CHALLENGES:

- How to use MRD in clinical practice - R. Owen
- What kind of trials do we need in the future to address open issues with MRD? - M. Attal

Panel discussion

19.00-19.40 **AGGRESSIVE DISEASE - EXTRAMEDULLARY DISEASE /
PLASMA CELL LEUKEMIA**

Chairmen: H.E. Johnsen, T. Plesner

Biology of aggressive disease - N.C. Munshi

Extramedullary disease - L. Rosiñol

Plasma cell leukemia - P. Musto

Panel discussion

19.40-20.30 **WELCOME COCKTAIL**

FRIDAY, APRIL 20, 2018

8.00-9.00 MEET THE EXPERTS

6 Simultaneous Sessions

- MGUS and SMM - **N. Giuliani, M.V. Mateos**
- MRD in clinical practice - **H. Avet-Loiseau, D. Hofste op Bruinink**
- Transplant strategies - **G. Jackson, C. Straka**
- Risk adapted therapy in NDMM young - **V. Montefusco, P. Sonneveld**
- How to incorporate new agents - **C. Driessen, S. Zweegman**
- Data manager: how to deal with data management issues - **S. Lonergan, R. Troia**

9.00-10.15 TREATMENT STRATEGY IN MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS

Chairmen: **H. Einsele, C. Straka**

Treatment strategy: optimal induction and autologous stem cell transplantation - **M. Cavo**

Transplant strategies: elderly and allo - **M. Mohty**

Post transplantation strategies - **P.L. McCarthy**

Geriatric assessment in the elderly - **A. Larocca**

Treatment strategy in the elderly - **S. Zweegman**

Panel discussion

10.15-11.10 RECOMMENDATIONS AND CHALLENGES: HOW TO MAKE SENSE OF THE MANY TREATMENT OPTIONS AVAILABLE AT DIAGNOSIS

Chairmen: **H. Goldschmidt, P.L. McCharty**

DEBATE: RISK ADAPTED THERAPY

- Are we ready? YES - **M.A. Dimopoulos**
- Are we ready? NO - **G.J. Morgan**

Cost/efficacy considerations - **M. Engelhardt**

What kind of trials do we need in the future to address open issues in NDMM? - **G. Cook**

Panel discussion

11.10-11.30 COFFEE BREAK and POSTER VIEWING

11.30-13.00 JANSSEN SPONSORED SYMPOSIUM Multiple Myeloma: what are your goals for treating patients in 2018?

Chairmen: **M. Cavo, M.V. Mateos**

Welcome and introduction - **M. Cavo**

Can we cure multiple myeloma? - **N. van de Donk**

What's on the near horizon for front-line treatment? - **M.V. Mateos**

Optimizing outcomes: the changing treatment landscape in relapsed and refractory MM - **P. Moreau**

Practical management considerations for the new therapeutic options in relapsed and refractory MM - **F. Gay**

Panel discussion

Summary and close - **M. Cavo**

13.00-13.30 PATIENT PERSPECTIVE: PATIENT ASSOCIATION TALKS

Chairman: **B.G.M. Durie**

IMF - International Myeloma Foundation - **B.G.M. Durie**

MPE - Myeloma Patients Europe - **A. Plate**

AIL - Italian Association against leukemia-lymphoma and myeloma - **F.N. Bombaci**

13.30-14.30 LUNCH and POSTER VIEWING

14.30-16.00 PRIME ONCOLOGY SPONSORED SYMPOSIUM supported by BRISTOL-MYERS SQUIBB Fitting the pieces together: treatment decisions for patients with relapsed/refractory Multiple Myeloma

Chairman: **P. Sonneveld**

Welcome and introduction - **P. Sonneveld**

Pop quiz on relapsed/refractory multiple myeloma - **P. Sonneveld**

Hot topic in multiple myeloma: the evolving role for immunotherapy in patients with relapsed/refractory disease - **G.J. Morgan**

Questions from the audience

Weighing the options at first relapse - **H. Einsele**

Questions from the audience

How do I choose? Treatment decisions after multiple lines of therapy - **M.A. Dimopoulos**

Questions from the audience

Burning questions and future directions in relapsed/refractory multiple myeloma: a panel discussion with the experts - **P. Sonneveld**

Post-activity assessment quiz and prIME Points - **P. Sonneveld**

Adjourn

16.00-16.50 **SPECIAL CONDITIONS - WALDENSTRÖM MACROGLOBULINEMIA**

Chairmen: X. Leleu, S.P. Treon

Diagnostic and prognostic challenges in WM - **S.P. Treon**

Novel targeted treatment options for WM: new challenges - **E. Kastiris**

Management of IgM related disorders - **M.J. Kersten**

Panel discussion

16.50-17.20 **COFFEE BREAK and POSTER VIEWING**

17.20-18.10 **SPECIAL CONDITIONS - AMYLOID LIGHT-CHAIN
AMYLOIDOSIS**

Chairmen: J. Bladé, G. Merlini

Mechanisms of disease and biomarkers - **G. Merlini**

Diagnosis, risk stratification and response assessment - **M. Minnema**

Established and novel therapies - **G. Palladini**

Panel discussion

18.10-18.50 **BEST ABSTRACTS I - ORAL PRESENTATIONS**

Chairmen: R. Hájek, F. Malavasi

SATURDAY, APRIL 21, 2018

8.00-9.00 **MEET THE EXPERTS**

6 Simultaneous Sessions

- Start of therapy in RRMM - **P. Moreau, A. Waage**
- Risk adapted therapy in NDMM elderly - **I.S. Nijhof, M.T. Petrucci**
- Special conditions - **M. Offidani, L. Rosiñol**
- Imaging: when and in which patients - **J. Hillengas, R. Zambello**
- Nurse: management of multiple myeloma patients from a nurse's perspective - **A. Bernardini, P.W.C. Bosman**
- Biology of multiple myeloma - **R. Hájek, M. Kaiser**

9.00-10.15 **TREATMENT STRATEGY IN RELAPSED/REFRACTORY
MULTIPLE MYELOMA PATIENTS: NOVEL THERAPIES,
WHEN AND IN WHICH PATIENTS?**

Chairmen: C. Driessen, S. Lonial

When to use novel proteasome inhibitors and immunomodulatory drugs - **F. Gay**

When to use other classes of drugs: HDACs, nuclear pore inhibitors, proteomics - **E.M. Ocio**

When to use monoclonal antibodies - **N. van de Donk**

When do we choose checkpoint inhibitors - **P. Rodriguez**

Which will be the best place for bispecific antibodies and novel cellular therapies - **H. Einsele**

Panel discussion

10.15-10.55 **BEST ABSTRACTS II - ORAL PRESENTATIONS**

Chairmen: H. Goldschmidt, E. Terpos

10.55-11.30 **COFFEE BREAK and POSTER VIEWING**

11.30-12.50 **RECOMMENDATIONS AND CHALLENGES:
HOW TO MAKE SENSE OF THE MANY TREATMENT OPTIONS
AVAILABLE AT RELAPSE**

Chairmen: M.A Dimopoulos, G. Jackson

DEBATE: START OF THERAPY

- Biological or clinical relapse? Biological - **M. Boccadoro**
- Biological or clinical relapse? Clinical - **S. Lonial**

How to use newest combinations: is there an optimal sequencing? - **X. Leleu**

Cost/efficacy considerations - **J.L. Harousseau**

What kind of trials do we need in the future to address open issues in RRMM? - **P. Moreau**

Panel discussion

12.50-13.30 **SIDE EFFECTS MANAGEMENT**

Chairmen: H. Ludwig, A. Waage

How I treat bone disease - **E. Terpos**

How I treat cardiovascular toxicity - **S. Brinthen**

How I treat infections - **M. Delforge**

How I treat renal failure - **H. Ludwig**

Panel discussion

13.30-13.40 **CONCLUSIONS AND FINAL GREETINGS**

13.40-14.30 **LIGHT LUNCH**

Turin

April 19-21, 2018

Lingotto Conference Center

MEETING VENUE

Lingotto Conference Center

Via Nizza, 280 - 10126 Turin - Italy

Ph +39.011.6311702 - Fax +39.011.6311789

www.centrocongressilingotto.it

SCIENTIFIC BOARD

Mario Boccardo (*Italy*)

Hermann Einsele (*Germany*)

Maria-Victoria Mateos (*Spain*)

Philippe Moreau (*France*)

Pieter Sonneveld (*The Netherlands*)

SCIENTIFIC SECRETARIAT

Francesca Gay

University of Turin, Turin

Niels van de Donk

VU University Medical Center, Amsterdam

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via Marconi 36 - 40122 Bologna - Italy

Ph +39 051 4210559 - Fax +39 051 4210174

E-mail: emn2018@ercongressi.it

www.ercongressi.it